Elicio Therapeutics Updates Nasdaq Ticker to ELTX

Ticker: ELTX · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1601485

Elicio Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyElicio Therapeutics, Inc. (ELTX)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: ticker-change, administrative, corporate-action

TL;DR

**Elicio Therapeutics changed its Nasdaq ticker to ELTX, effective January 9, 2024.**

AI Summary

Elicio Therapeutics, Inc. filed an 8-K on January 9, 2024, to update its trading symbol from its previous symbol to ELTX on The Nasdaq Global Select Market. This change is a routine administrative update following a corporate action, ensuring the company's common stock, with a $0.01 par value per share, is correctly identified for trading. For investors, this matters because it confirms the company's continued listing and provides the correct ticker for tracking their investment.

Why It Matters

This filing confirms Elicio Therapeutics' continued listing on The Nasdaq Global Select Market under its new ticker symbol, ELTX, which is essential for investors to accurately track their shares.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative, reporting a change in the company's trading symbol, and does not indicate any operational or financial risk.

Analyst Insight

Investors should update their watchlists and brokerage accounts with the new ticker symbol, ELTX, to ensure they are tracking the correct stock for Elicio Therapeutics, Inc.

Key Numbers

  • $0.01 — Par value per share (The stated par value of Elicio Therapeutics' common stock.)

Key Players & Entities

  • Elicio Therapeutics, Inc. (company) — the registrant
  • ELTX (other) — new trading symbol
  • The Nasdaq Global Select Market (other) — exchange where stock is registered
  • $0.01 (dollar_amount) — par value per share
  • January 9, 2024 (other) — date of earliest event reported

FAQ

What is the new trading symbol for Elicio Therapeutics, Inc.?

The new trading symbol for Elicio Therapeutics, Inc. is ELTX, as stated in the filing under 'Common Stock, $0.01 par value per share ELTX The Nasdaq Global Select Market'.

On which stock exchange is Elicio Therapeutics, Inc. common stock registered?

Elicio Therapeutics, Inc. common stock is registered on The Nasdaq Global Select Market, as indicated in the filing.

What is the par value per share of Elicio Therapeutics, Inc. common stock?

The par value per share of Elicio Therapeutics, Inc. common stock is $0.01, as specified in the filing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 9, 2024, as stated under 'Date of Report (date of earliest event reported): January 9, 2024'.

Is Elicio Therapeutics, Inc. considered an emerging growth company?

Yes, Elicio Therapeutics, Inc. is an emerging growth company, as indicated by the checked box 'Emerging growth company ☑' in the filing.

Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-09 08:11:00

Key Financial Figures

  • $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq

Filing Documents

01

Item 8.01 Other Events. On January 9, 2024 , Elicio Therapeutics, Inc. (the "Company") issued a press release announcing the publication of updated preliminary data from the Company's ongoing Phase 1 (AMPLIFY-201) solid tumor study of its lead asset, ELI-002, in Nature Medicine . A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. A ttached as Exhibit 99.2 and incorporated herein by reference is an updated version of the Company's corporate presentation, which was uploaded to the Company's website on January 9, 2024.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release of Elicio Therapeutics, Inc., dated January 9, 2024 99.2 Corporate presentation dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Robert Connelly President and Chief Executive Officer (Principal Executive Officer) Date: January 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.